NASDAQ: RNACCartesian Therapeutics Inc Stock Ownership - Who owns Cartesian Therapeutics?
Insider buying vs selling
Have Cartesian Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Milos Miljkovic | Chief Medical Officer | 2026-01-06 | 3,573 | $6.82 | $24.37kSell |
| Carsten Brunn | President and CEO | 2026-01-06 | 23,766 | $6.82 | $162.08kSell |
| Blaine Davis | Chief Financial Officer | 2026-01-06 | 10,591 | $6.82 | $72.23kSell |
| Emily English | Chief Operations Officer | 2025-12-30 | 7,500 | $3.30 | $24.75kBuy |
| Timothy C. Barabe | Director | 2025-12-04 | 30,000 | $6.86 | $205.80kBuy |
| Emily English | Chief Operations Officer | 2025-11-28 | 7,500 | $3.30 | $24.75kBuy |
| Emily English | Chief Operations Officer | 2025-05-12 | 7,500 | $3.30 | $24.75kBuy |
RNAC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when RNAC insiders and whales buy or sell their stock.
RNAC Shareholders
What type of owners hold Cartesian Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Timothy A. Springer | 38.05% | 11,179,069 | $69.53M | Insider |
| Elizabeth Hoge | 19.81% | 5,820,260 | $36.20M | Insider |
| Murat Kalayoglu | 19.81% | 5,820,260 | $36.20M | Insider |
| Amir Nashat | 9.11% | 2,676,234 | $16.65M | Insider |
| Polaris Venture Management Co V LLC | 6.39% | 1,876,020 | $11.67M | Insider |
| Carl L. Gordon | 6.21% | 1,825,415 | $11.35M | Insider |
| Orbimed Advisors LLC | 6.21% | 1,825,415 | $11.35M | Insider |
| Flagship Ventures Fund 2007 LP | 5.62% | 1,651,862 | $10.27M | Insider |
| Rusnano | 5.02% | 1,476,177 | $9.18M | Insider |
| Fmr LLC | 4.65% | 1,366,989 | $8.50M | Institution |
RNAC vs Biotech Stocks
Cartesian Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.